Cetera Investment Advisers Decreases Stake in Tenet Healthcare Corporation $THC

Cetera Investment Advisers cut its stake in Tenet Healthcare Corporation (NYSE:THC) by 7.9% in the first quarter, Holdings Channel reports. The firm owned 42,991 shares of the company’s stock after selling 3,689 shares during the period. Cetera Investment Advisers’ holdings in Tenet Healthcare were worth $8,113,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in shares of Tenet Healthcare during the fourth quarter valued at $248,494,000. Wellington Management Group LLP lifted its position in Tenet Healthcare by 1,114.2% during the 4th quarter. Wellington Management Group LLP now owns 1,135,801 shares of the company’s stock worth $225,706,000 after acquiring an additional 1,042,260 shares during the period. Boston Partners grew its stake in Tenet Healthcare by 38.8% during the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after purchasing an additional 880,413 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Tenet Healthcare by 62.3% in the third quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock valued at $380,989,000 after purchasing an additional 720,160 shares during the period. Finally, Alliancebernstein L.P. lifted its holdings in shares of Tenet Healthcare by 375.7% during the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after purchasing an additional 624,125 shares during the period. 95.44% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on THC. KeyCorp decreased their price objective on shares of Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Truist Financial raised their target price on shares of Tenet Healthcare from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a research report on Monday. TD Cowen increased their price target on Tenet Healthcare from $233.00 to $263.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Barclays boosted their price objective on Tenet Healthcare from $240.00 to $271.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $268.50.

Tenet Healthcare Stock Up 0.9%

THC stock opened at $254.88 on Friday. Tenet Healthcare Corporation has a one year low of $156.71 and a one year high of $262.68. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41. The firm’s fifty day moving average is $192.10 and its 200 day moving average is $199.35. The firm has a market cap of $21.96 billion, a PE ratio of 9.83, a P/E/G ratio of 0.96 and a beta of 1.27.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings data on Thursday, July 23rd. The company reported $6.12 earnings per share for the quarter, topping analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business had revenue of $6.04 billion during the quarter, compared to the consensus estimate of $5.43 billion. During the same quarter in the prior year, the firm posted $4.02 earnings per share. The company’s revenue was up 6.8% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. On average, research analysts forecast that Tenet Healthcare Corporation will post 21.09 EPS for the current year.

Insider Activity at Tenet Healthcare

In other news, Director J Robert Kerrey sold 5,638 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total transaction of $983,943.76. Following the transaction, the director owned 16,804 shares in the company, valued at $2,932,634.08. This trade represents a 25.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher S. Lynch sold 3,837 shares of Tenet Healthcare stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.44, for a total transaction of $934,079.28. Following the completion of the sale, the director directly owned 9,568 shares in the company, valued at $2,329,233.92. This represents a 28.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,353 shares of company stock valued at $7,683,517 in the last ninety days. 0.97% of the stock is currently owned by company insiders.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.